Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in heathy subjects

Diabetes

Volumn 54, Issue 7, 2005, Pages 2212-2218

  Meier, Juris J ^a,b   Kemmeries, Guido ^a   Holst, Jens J ^c   Nauck, Michael A ^a,d,e  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Diabeteszentrum   (Germany)

^e DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE OXIDASE; INSULIN; METOCLOPRAMIDE; MOTILIUM SAFT; PANCREAS POLYPEPTIDE; PHENOLSULFONPHTHALEIN; PLACEBO; PROPULSIN SAFT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CAPILLARY BLOOD; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG ANTAGONISM; DRUG MECHANISM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STOMACH EMPTYING; VENOUS BLOOD;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; CISAPRIDE; DOMPERIDONE; EATING; ERYTHROMYCIN; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; METOCLOPRAMIDE; PEPTIDE FRAGMENTS; PLACEBOS; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 21344454659     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.7.2212     Document Type: Article

References (45)

1. Elrick H, Stimmler L, Hlad CJ, Arai Y: Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082, 1964
2. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
3. Creutzfeldt W, Nauck M: Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177, 1992
4. Brown JC: A astric inhibitory polypeptide. I: the amino acid composition and the tryptic peptides. Can J Biochem 49:255-261, 1971
5. Pederson RA, Brown JC: The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas. Endocrinology 99:780-785, 1976
6. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300-1304, 1987
7. Kolligs F, Fehmann HC, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19, 1995
8. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93, 1999
9. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273:E981-E988, 1997
10. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725, 2003
11. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36:857-862, 1993
12. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M: Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 19:177-194, 2002
13. George JD: New clinical method for measuring the rate of gastric emptying; the double sampling test meal. Gut 9:237-242, 1968
14. Hurwitz A: Measuring gastric volume by dilution. Gut 22:85-93, 1981
15. Ørskov C, Holst JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165-174, 1987
16. Holst JJ: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207:381-388, 1982
17. Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581, 2000
18. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ: The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597-601, 1997
19. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
20. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 20:876-913, 1999
21. Unger RH, Eisentraut AM: Entero-insular axis. Arch. Intern Med 123:261-266, 1969
22. Dupré J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828, 1973
23. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
24. Vilsbøll T, Krarup T, Madsbad S, Holst JJ: Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121, 2003
25. Ipp E, Dobbs R, Harris V, Arimura A, Vale W, Unger RU: The effect of gastrin, gastric inhibitory polypeptide, secretion, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas. J Clin Invest 60:1216-1219, 1977
26. Zawalich WS, Diaz VA, Zawalich KC: Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718 [corrected]. Diabetes 37:1432-1437, 1988
27. Schwartz JG, Guan D, Green GM, Phillips WT: Treatment with an oral proteinase inhibitor slows gastric emptying and acutely reduces glucose and insulin levels after a liquid meal in type II diabetic patients. Diabetes Care 17:255-262, 1994
28. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M: Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 89:3431-3435, 2004
29. Polak JM, Bloom SR, Kuzio M, Brown JC, Pearse AGE: Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum. Gut 14:284-288, 1973
30. Mortensen K, Petersen LL, Holst JJ, Ørskov C: GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189-196, 2003
31. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL: Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 88:3829-3834, 2003
32. Ueno N, Inui A, Asakawa A, Takao F, Tani S, Komatsu Y, Itoh Z, Kasuga M: Erythromycin improves glycaemic control in patients with type II diabetes mellitus. Diabetologia 43:411-415, 2000
33. Stacher G, Schernthaner G, Francesconi M, Kopp HP, Bergmann H, Stacher-Janotta G, Weber U: Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial. J Clin Endocrinol Metab 84:2357-2362, 1999
34. Thompson DG, Wingate DL, Thomas M, Harrison D: Gastric emptying as a determinant of the oral glucose tolerance test. Gastroenterology 82:51-55, 1982
35. Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH: Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci 30:10-15, 1985
36. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJ: Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 30:1-9, 1985
37. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL: Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36:652-681, 1988
38. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R: Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med 322:1028-1031, 1990
39. Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, O'Neill G, Van Der Ploeg LH, Evans J, Patchett AA, Smith RG, Howard AD: Receptor for motilin identified in the human gastrointestinal system. Science 284:2184-2188, 1999
40. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva Penacarrillo ML, Ulusoy NB: Glucagon-like peptide-1 inhibits gastric emptying via vagal zfferent-mediated central mechanisms. Am J Physiol Gastroenterol Liver 273:G920-G927, 1997
41. Wettergren A, Wojdemann M, Holst JJ: Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275:G984-G992, 1998
42. Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M: Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1 (7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 156:177-186, 1998
43. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725, 1995
44. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
45. Meier JJ, Nauck MA: The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5:402-410, 2004